Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC).
Martín Zarbá(University of Calgary), Daniel Yick Chin Heng(University of Calgary), Naveen S. Basappa, Talal El Zarif(Yale University), Aly‐Khan A. Lalani(Juravinski Cancer Centre), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Connor Wells(Queen Mary University of London), Arnoud J. Templeton(University of Basel), Toni K. Choueiri(Harvard University), Rana R. McKay(University of California San Diego), Georg A. Bjarnason(Sunnybrook Health Science Centre), Kosuke Takemura(Japanese Foundation For Cancer Research), Lori Wood(Dalhousie University), Hedyeh Ebrahimi(City of Hope), Thomas Powles(Queen Mary University of London), Haoran Li(University of Utah), Guillermo de Velasco(Dana-Farber Cancer Institute), Cristina Suárez(Vall d'Hebron Hospital Universitari), Evan Ferrier, Lavinia Spain(Royal Marsden NHS Foundation Trust)
Cited by 10
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k